A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF ABEMACICLIB AND LETROZOLE IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE RARE OVARIAN CANCER

被引：0
|
作者：
Ottenbourgs, Tine [1 ]
Van Nieuwenhuysen, Els [1 ]
机构：
[1] UZ Leuven, Leuven, Belgium
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷
关键词：
D O I：
10.1136/ijgc-2023-ESGO.869
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
124
引用
收藏
页码：A409 / A410
页数：2
相关论文
共 50 条
  • [21] Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers
    Colon-Otero, Gerardo
    Weroha, S. John
    Foster, Nathan R.
    Haluska, Paul
    Hou, Xiaonan
    Wahner-Hendrickson, Andrea E.
    Jatoi, Aminah
    Block, Matthew S.
    Dinh, Tri A.
    Robertson, Matthew W.
    Copland, John A.
    GYNECOLOGIC ONCOLOGY, 2017, 146 (01) : 64 - 68
  • [22] A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
    Baselga, Jose
    Morales, Serafin M.
    Awada, Ahmad
    Blum, Joanne L.
    Tan, Antoinette R.
    Ewertz, Marianne
    Cortes, Javier
    Moy, Beverly
    Ruddy, Kathryn J.
    Haddad, Tufia
    Ciruelos, Eva M.
    Vuylsteke, Peter
    Ebbinghaus, Scot
    Im, Ellie
    Eaton, Lamar
    Pathiraja, Kumudu
    Gause, Christine
    Mauro, David
    Jones, Mary Beth
    Rugo, Hope S.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 535 - 544
  • [23] A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
    José Baselga
    Serafin M. Morales
    Ahmad Awada
    Joanne L. Blum
    Antoinette R. Tan
    Marianne Ewertz
    Javier Cortes
    Beverly Moy
    Kathryn J. Ruddy
    Tufia Haddad
    Eva M. Ciruelos
    Peter Vuylsteke
    Scot Ebbinghaus
    Ellie Im
    Lamar Eaton
    Kumudu Pathiraja
    Christine Gause
    David Mauro
    Mary Beth Jones
    Hope S. Rugo
    Breast Cancer Research and Treatment, 2017, 163 : 535 - 544
  • [24] Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial
    Johnston, Stephen
    Puhalla, Shannon
    Wheatley, Duncan
    Ring, Alistair
    Barry, Peter
    Holcombe, Chris
    Boileau, Jean Francois
    Provencher, Louise
    Robidoux, Andre
    Rimawi, Mothaffar
    McIntosh, Stuart A.
    Shalaby, Ibrahim
    Stein, Robert C.
    Thirlwell, Michael
    Dolling, David
    Morden, James
    Snowdon, Claire
    Perry, Sophie
    Cornman, Chester
    Batten, Leona M.
    Jeffs, Lisa K.
    Dodson, Andrew
    Martins, Vera
    Modi, Arjun
    Osborne, C. Kent
    Pogue-Geile, Katherine L.
    Cheang, Maggie Chon U.
    Wolmark, Norman
    Julian, Thomas B.
    Fisher, Kate
    MacKenzie, Mairead
    Wilcox, Maggie
    Bartlett, Cynthia Huang
    Koehler, Maria
    Dowsett, Mitch
    Bliss, Judith M.
    Jacobs, Samuel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 178 - +
  • [25] Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study
    Mustacchi, G.
    Mansutti, M.
    Sacco, C.
    Barni, S.
    Farris, A.
    Cazzaniga, M.
    Cozzi, M.
    Dellach, C.
    ANNALS OF ONCOLOGY, 2009, 20 (04) : 655 - 659
  • [26] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
  • [27] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Yardley, Denise A.
    Dees, E. Claire
    Myers, Stephen D.
    Li, Sherry
    Healey, Paul
    Wang, Zhixiao
    Brickman, Marla J.
    Paolini, Jolanda
    Kern, Kenneth A.
    Citrin, Dennis L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767
  • [28] Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Egelston, Colt A.
    Guo, Weihua
    Padam, Simran
    Tang, Aileen
    Martinez, Norma
    Schmolze, Daniel
    Presant, Cary
    Ebrahimi, Behnam
    Yeon, Christina
    Sedrak, Mina
    Patel, Niki
    Portnow, Jana
    Lee, Peter
    Mortimer, Joanne
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 11 - 20
  • [29] Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
    Prat, Aleix
    Saura, Cristina
    Pascual, Tomas
    Hernando, Cristina
    Munoz, Montserrat
    Pare, Laia
    Gonzalez Farre, Blanca
    Fernandez, Pedro L.
    Galvan, Patricia
    Chic, Nuria
    Gonzalez Farre, Xavier
    Oliveira, Mafalda
    Gil-Gil, Miguel
    Arumi, Miriam
    Ferrer, Neus
    Montano, Alvaro
    Izarzugaza, Yann
    Llombart-Cussac, Antonio
    Bratos, Raquel
    Gonzalez Santiago, Santiago
    Martinez, Eduardo
    Hoyos, Sergio
    Rojas, Beatriz
    Antonio Virizuela, Juan
    Ortega, Vanesa
    Lopez, Rafael
    Celiz, Pamela
    Ciruelos, Eva
    Villagrasa, Patricia
    Gavila, Joaquin
    LANCET ONCOLOGY, 2020, 21 (01): : 33 - 43
  • [30] Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
    Ciruelos, E. M.
    Hamilton, E. P.
    Kim, S-B.
    Im, Y-H.
    Solis, E. Segui
    Saenz, J. A. Garcia
    Di Sanzo, A.
    Lizarbe, M. Dominguez
    Wasserman, T.
    Theall, K. P.
    Ibrahim, N. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S370 - S370
12345